LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis
Citations
833 citations
522 citations
Cites background from "LDH-A silencing suppresses breast c..."
...Knockdown of lactate dehydrogenase A (LDHA), which converts pyruvate to lactate, significantly curbed the clonogenicity of lymphoma cells and inhibited tumorigenicity of mammary cancer, lung cancer, and neuroblastomas with amplified NMYC in mice (Shim et al. 1997; Fantin et al. 2006; Xie et al. 2009; Le et al. 2010; Qing et al. 2010; Wang et al. 2012)....
[...]
...…pyruvate to lactate, significantly curbed the clonogenicity of lymphoma cells and inhibited tumorigenicity of mammary cancer, lung cancer, and neuroblastomas with amplified NMYC in mice (Shim et al. 1997; Fantin et al. 2006; Xie et al. 2009; Le et al. 2010; Qing et al. 2010; Wang et al. 2012)....
[...]
399 citations
Cites result from "LDH-A silencing suppresses breast c..."
...Previous work from others and us has shown that that LDH-A-suppressed cancer cell lines exhibit reduced tumor progression in xenograft models (Fan et al., 2011a; Fantin et al., 2006; Wang et al., 2012)....
[...]
375 citations
Cites background from "LDH-A silencing suppresses breast c..."
...In vivo xenografts of breast cancer cell lines also found that cell lines with LDHA knocked down had elevated Bax, cleaved PARP, cleaved caspase-9, cytosolic cytochrome C and superoxide anion expression but decreased Bcl-2 expression and mitochondrial membrane potential (137)....
[...]
...Multiple in vitro and in vivo xenograft mouse model studies have found that LDHA knockdown cells treated with N-acetyl-L-cysteine (NAC), an antioxidant that breaks disulfide bonds, prevented or partially prevented the induced generation of ROS and apoptosis (113, 137, 140)....
[...]
313 citations
References
2,524 citations
2,423 citations
Additional excerpts
..., by the so-called quick score (Q) (Q = P 9 I; maximum = 300) [22]....
[...]
1,403 citations
"LDH-A silencing suppresses breast c..." refers background in this paper
...Besides hexokinase, G6PD, GAPDH, and TKTL1 were also well demonstrated in laboratory to be potential targets [6]....
[...]
...Some key enzymes in the process have already become molecular targets, and corresponding inhibitors have demonstrated significant anti-cancer effects and have been approved for clinical trials [6]....
[...]